

TFW

Docket No. 0575/66697/JPW/AJM/DNS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rashid A. Fawwaz
Serial No. : 10/608,841
Filed : June 26, 2003
For : USE OF STREPTAVIDIN TO INHIBIT TRANSPLANT
REJECTION

1185 Avenue of the Americas
New York, New York 10036
January 31, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit A**) and are also listed below.

This Second Supplemental Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Second Supplemental Information Disclosure Statement should be entered and considered. Copies of the documents listed below as items 1-2 are attached hereto as **Exhibits 1-2**.

1. Fawwaz, R.A., et al. (1999) Radiolabeled Streptavidin: A Potential Breast Tumor Imaging Agent, *Ann Nucl Med Sci*, 12, 137-141 (**Exhibit 1**); and

Applicants: Rashid A. Fawwaz
Serial No.: 10/608,841
Filed: June 26, 2003
Page 2


2. Fawwaz, R.A., et al. (1997) Antiproliferative Effect of Streptavidin in the Treatment of Human Breast Cancer Xenograft (MCF-7) Growing in Nude Mice, *Proceedings of the American Assoc. for Cancer Res*, 38, 612 (**Exhibit 2**).

Applicants request that the Examiner review the references and make them of record in the subject application.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.


No fee is deemed necessary in connection with the filing of this Second Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Alan J. Morrison
Reg. No. 37,399
Date 1/31/05



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 66697/JPW/AJM/DNS		Serial No. 10/608,841			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Rashid A. Fawwaz					
					Filing Date June 26, 2003		Group			
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS										
		Document Number				Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
		Fawwaz, R.A., et al. (1999) Radiolabeled Streptavidin: A Potential Breast Tumor Imaging Agent, <i>Ann Nucl Med Sci</i> , 12, 137-141;								
		Fawwaz, R.A., et al. (1997) Antiproliferative Effect of Streptavidin in the Treatment of Human Breast Cancer Xenograft (MCF-7) Growing in Nude Mice, <i>Proceedings of the American Assoc. for Cancer Res</i> , 38, 612;								
EXAMINER		DATE CONSIDERED								
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

Applicants: Rashid A. Fawwaz
Serial No.: 10/608,841
Filed: June 26, 2003
Exhibit A